On December 15, 2025, Link Cell Therapies, an oncology cell therapy company, announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the transaction.

Link's proprietary logic-gating technologies allow for safe targeting of multiple antigens that are co-expressed on cancer cells but do not overlap or only minimally overlap in their normal healthy tissue expression. This platform enables the creation of next-generation CAR-T therapeutics for solid and liquid cancers built upon an entirely new landscape of "clean" target pairs.

The Wilson Sonsini team that advised Link Cell Therapies on the transaction included:

Corporate
Christina Poulsen
Sean Mihaljevich
Angelica Lee
Jennifer Gu

Technology Transactions
Norm Hovijitra
Alex DeLaney

Patents and Innovations
Laurie McNamara
Lou Lieto
Alicia Umpierre

For more information, please see Link Cell Therapies’ news release. Additional coverage can be found on Fierce Biotech and The Pharma Letter (subscription required).